Dr. Kazandjian on Novel Therapeutic Targets in Multiple Myeloma

Partner | Cancer Centers | <b>Sylvester Comprehensive Cancer Center</b>

Dickran G. Kazandjian, MD, discusses novel therapeutic targets in multiple myeloma.

Dickran G. Kazandjian, MD, professor of medicine, Myeloma Program, Sylvester Comprehensive Cancer Center, discusses novel therapeutic targets in multiple myeloma.

Bispecific T-cell engagers and CAR T-cell therapies directed toward novel targets, such as GPRC5D, are emerging in multiple myeloma, says Kazandjian.

Additionally, SLAMF7 is emerging as a potential target for CAR T-cell therapy in multiple myeloma, Kazandjian says. The SLAMF7-targeted monoclonal antibody elotuzumab (Empliciti) was approved in 2018 by the FDA for use in combination with pomalidomide (Pomalyst) and dexamethasone in certain patients with relapsed/refractory multiple myeloma.

In addition to novel targets, CAR T-cell therapies with improved stimulatory and binding domains are emerging in this disease, Kazandjian explains. For example, the phase 1/2 EVOLVE study (NCT03430011) is evaluating a newer CAR T-cell product orvacabtagene autoleucel (JCARH125) in patients with relapsed/refractory multiple myeloma, Kazandjian says. This therapy appears to have a low affinity for binding soluble BCMA, which could improve the therapy’s ability to bind to cell-surface BCMA on myeloma cells, concludes Kazandjian.